Platelet-derived growth factor receptor inhibitor imatinib mesylate and docetaxel: a modular phase I trial in androgen-independent prostate cancer.
Hofer
Matthias D
MD
Rubin
Mark A
MA
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001549:Benzamides; D017321:Clinical Trials, Phase I as Topic; D000077143:Docetaxel; D006801:Humans; D000068877:Imatinib Mesylate; D007150:Immunohistochemistry / Q000592:standards; D008297:Male; D010879:Piperazines / Q000008:administration & dosage; D011471:Prostatic Neoplasms; D011743:Pyrimidines / Q000008:administration & dosage; D020797:Receptor, Platelet-Derived Growth Factor beta / Q000032:analysis / Q000378:metabolism*; D012107:Research Design; D043823:Taxoids / Q000008:administration & dosage
D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D043823:Taxoids; D000077143:Docetaxel; D000068877:Imatinib Mesylate; D020797:Receptor, Platelet-Derived Growth Factor beta